A new chemical technology uses cancer cells’ own protein-degrading machinery to destroy, rather than merely inhibit, cancer proteins. Researchers developed the strategy as a way to develop inhibitors of “undruggable” proteins and overcome drug resistance, a common shortcoming of targeted therapies. Resistance arises when tumors that originally responded to a particular therapy manage to circumvent the drug’s effects and resume their growth.